Skip to content
value.today

Mustang Bio, Inc.

🇺🇸 New York, New York, USABiotechnologyFounded 2015

Formerly Mustang Therapeutics, Inc.

Total raised
$233 M
6 rounds on record
Latest round
$95 M
Jan 2017
First round on record
Sep 2016
Today
Went public
See the company page

Mustang Bio, Inc. is listed today as Mustang Bio, Inc.: market value, financials and filings are on its company page.

Funding rounds

6 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Mustang Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2024$3 MPrivate placement after listing$2 to $10 million

Mustang Bio, Inc.: Private sale, Jun 2024

Investors in this round

1 investor had bought by the notice of Jun 24, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Mustang Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$175,931
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James B Murphy · Executive Officer · Interim Chief Financial Officer
  • Manuel B. Litchman, M.D. · Executive Officer, Director · President and Chief Executive Officer
  • Adam J. Chill · Director
  • Lindsay A. Rosenwald, M.D. · Director
  • Michael J. Zelefsky, M.D. · Director
  • Michael S. Weiss · Director
  • Neil A. Herskowitz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 000000375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “In connection with the registered direct offering concurrent with the private placement, the placement agent received $175,931 and warrants to purchase up to 367,800 shares of common stock exercisable at $0.5125 per share.”
  • On the amounts: “The offering amount reflects the aggregate purchase price received and exercise price due to the Company assuming cash exercise of all warrants issued to the accredited investor and placement agent in the private placement under Rule 506(b).”

Signed by Manuel B. Litchman, M.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 24, 2024. Read the notice at the SEC.

optionsSEC
Oct 2023$5 MPrivate placement after listing$2 to $10 million

Mustang Bio, Inc.: Private sale, Oct 2023

Investors in this round

1 investor had bought by the notice of Nov 3, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Mustang Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$308,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eliot S. Lurier · Executive Officer
  • Manuel S. Litchman, M.D. · Executive Officer, Director
  • Adam J. Chill · Director
  • Lindsay A. Rosenwald, M.D. · Director
  • Michael J. Zelefsky, M.D. · Director
  • Michael S. Weiss · Director
  • Neil A. Herskowitz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “In connection with the registered direct offering concurrent with the private placement, the placement agent received $308,000.08 and warrants to purchase up to 155,294 shares of common stock exercisable at $2.125 per share.”
  • On the amounts: “The offering amount reflects the aggregate purchase price received and exercise price due to the Company assuming cash exercise of all warrants issued to the accredited investor and placement agent in the private placement under Rule 506(b).”

Signed by Matthew Wein, General Counsel. Source: SEC Form D, newest notice filed Nov 3, 2023. Read the notice at the SEC.

equity, optionsSEC
Jan 2017$95 MNo. 6$50 to $250 million

Mustang Bio, Inc.: Raise no. 6, Jan 2017

Investors in this round

1,086 investors had bought by the notice of Feb 15, 2017: 1,086 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Mustang Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$95 M of $100 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$9,478,571
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael S. Weiss · Executive Officer, Director
  • Lindsay A. Rosenwald · Director
  • Neil A. Herskowitz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation (CRD 7569) · broker-dealer National Securities Corporation (CRD 7569) · New York, New YorkSold in all US states

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by Michael S. Weiss, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 15, 2017. Read the notice at the SEC.

equity, optionsSEC
Dec 2016$39 MNo. 5$10 to $50 million

Mustang Bio, Inc.: Raise no. 5, Dec 2016

Investors in this round

519 investors had bought by the notice of Jan 13, 2017: 519 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Mustang Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$39 M of $70 M offered; $31 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,929,688
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael S. Weiss · Executive Officer, Director
  • Lindsay A. Rosenwald · Director
  • Neil A. Herskowitz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation (CRD 7569) · broker-dealer National Securities Corporation (CRD 7569) · New York, New YorkSold in all US states

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by Michael S. Weiss, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 13, 2017. Read the notice at the SEC.

equity, optionsSEC
Dec 2016$35 MNo. 4$10 to $50 million

Mustang Bio, Inc.: Raise no. 4, Dec 2016

Investors in this round

437 investors had bought by the notice of Jan 13, 2017: 437 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Mustang Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$35 M of $70 M offered; $35 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,518,708
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael S. Weiss · Executive Officer, Director
  • Lindsay A. Rosenwald · Director
  • Neil A. Herskowitz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation (CRD 7569) · broker-dealer National Securities Corporation (CRD 7569) · New York, New YorkSold in all US states

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by Michael S. Weiss, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 13, 2017. Read the notice at the SEC.

equity, optionsSEC
Nov 2016$32 MNo. 3$10 to $50 million

Mustang Bio, Inc.: Raise no. 3, Nov 2016

Investors in this round

390 investors had bought by the notice of Dec 13, 2016: 390 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Mustang Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$32 M of $70 M offered; $38 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,208,658
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael S. Weiss · Executive Officer, Director
  • Lindsay A. Rosenwald · Director
  • Neil A. Herskowitz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation (CRD 7569) · broker-dealer National Securities Corporation (CRD 7569) · New York, New YorkSold in all US states

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by Michael S. Weiss, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 13, 2016. Read the notice at the SEC.

equity, optionsSEC
Oct 2016$20 MNo. 2$10 to $50 million

Mustang Bio, Inc.: Raise no. 2, Oct 2016

Investors in this round

222 investors had bought by the notice of Nov 4, 2016: 222 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Mustang Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $70 M offered; $50 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,973,518
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael S. Weiss · Executive Officer, Director
  • Lindsay A. Rosenwald · Director
  • Neil A. Herskowitz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation (CRD 7569) · broker-dealer National Securities Corporation (CRD 7569) · New York, New YorkSold in all US states

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by Michael S. Weiss, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 4, 2016. Read the notice at the SEC.

equity, optionsSEC
Sep 2016$12 MNo. 1$10 to $50 million

Mustang Bio, Inc.: Raise no. 1, Sep 2016

Investors in this round

133 investors had bought by the notice of Oct 17, 2016: 133 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Mustang Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $70 M offered; $58 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,264,641
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael S. Weiss · Executive Officer, Director
  • Lindsay A. Rosenwald · Director
  • Neil A. Herskowitz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation (CRD 7569) · broker-dealer National Securities Corporation (CRD 7569) · New York, New YorkSold in all US states

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by Michael S. Weiss, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 17, 2016. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Mustang Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2024).

    SEC Form D · Jun 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2024

That is all the official record says: Mustang Bio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Mustang Bio, Inc. are on record.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Mustang Bio, Inc.
InvestorKindAmountRoundRoleSource
Fortress Biotech, Inc.Companynot statednot statedHeld preferred stock, 10% owner (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 1,086 investors.

Largest shareholders today

Institutions holding Mustang Bio, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Mustang Bio, Inc.
NameRoleNamed in
James B MurphyInterim Chief Financial OfficerJun 2024
Manuel B. Litchman, M.D.President and Chief Executive OfficerJun 2024
Eliot S. LurierExecutive officerNov 2023
Manuel S. Litchman, M.D.Executive officerNov 2023
Michael S. WeissExecutive officerFeb 2017
Adam J. ChillDirectorJun 2024
Lindsay A. Rosenwald, M.D.DirectorJun 2024
Manuel B. Litchman, M.D.President and Chief Executive OfficerJun 2024
Michael J. Zelefsky, M.D.DirectorJun 2024
Michael S. WeissDirectorJun 2024
Neil A. HerskowitzDirectorJun 2024
Manuel S. Litchman, M.D.DirectorNov 2023
Lindsay A. RosenwaldDirectorFeb 2017

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.